Enhanced Inflammation is a Marker for Risk of Post-Infarct Ventricular Dysfunction and Heart Failure (scientific article published on 26 January 2020)

Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: The Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology:

Q22242896

Epidemiology of Heart Failure and Left Ventricular Systolic Dysfunction after Acute Myocardial Infarction: Prevalence, Clinical Characteristics, and Prognostic Importance

Q22252543

Post-infarction inflammation and left ventricular remodeling: a double-edged sword

Q26865353

Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein

Q29547752

Left ventricular function and C-reactive protein levels in acute myocardial infarction

Q33761764

Randomised trial of effect of amiodarone on mortality in patients with left-ventricular dysfunction after recent myocardial infarction: EMIAT. European Myocardial Infarct Amiodarone Trial Investigators

Q34420012

Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators

Q34539986

The effect of interleukin-1 receptor antagonist therapy on markers of inflammation in non-ST elevation acute coronary syndromes: the MRC-ILA Heart Study

Q35059517

Usefulness of C-reactive protein as a marker of early post-infarct left ventricular systolic dysfunction

Q36031419

Value of C-reactive protein in predicting left ventricular remodelling in patients with a first ST-segment elevation myocardial infarction

Q36225152

Effects of interleukin-1 blockade with anakinra on adverse cardiac remodeling and heart failure after acute myocardial infarction [from the Virginia Commonwealth University-Anakinra Remodeling Trial (2) (VCU-ART2) pilot study].

Q36816882

Comparative value of simple inflammatory markers in the prediction of left ventricular systolic dysfunction in postacute coronary syndrome patients.

Q37202126

Preprocedural C-Reactive Protein Predicts Outcomes after Primary Percutaneous Coronary Intervention in Patients with ST-elevation Myocardial Infarction a systematic meta-analysis.

Q37609683

Early C-reactive protein in the prediction of long-term outcomes after acute coronary syndromes: a meta-analysis of longitudinal studies

Q37701610

Anti-inflammatory strategies for ventricular remodeling following ST-segment elevation acute myocardial infarction

Q38188327

Inflammatory markers in ST-elevation acute myocardial infarction

Q38355385

Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease

Q38606033

Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two-Dimensional Echocardiograms

Q38776803

The Biological Basis for Cardiac Repair After Myocardial Infarction: From Inflammation to Fibrosis.

Q38875774

The association of left ventricular ejection fraction with clinical outcomes after myocardial infarction: Findings from the Acute Coronary Treatment and Intervention Outcomes Network (ACTION) Registry-Get With the Guidelines (GWTG) Medicare-linked d

Q39510699

Relationship of TIMI myocardial perfusion grade to mortality after administration of thrombolytic drugs

Q41714484

Heart Failure With Preserved, Mid-Range, and Reduced Ejection Fraction: The Misleading Definition of the New Guidelines

Q42358715

Concentrations of C-reactive protein and B-type natriuretic peptide 30 days after acute coronary syndromes independently predict hospitalization for heart failure and cardiovascular death

Q44279052

Predictors of the first heart failure hospitalization in patients who are stable survivors of myocardial infarction complicated by pulmonary congestion and/or left ventricular dysfunction: a VALIANT study

Q44812183

Interleukin-1 blockade with anakinra to prevent adverse cardiac remodeling after acute myocardial infarction (Virginia Commonwealth University Anakinra Remodeling Trial [VCU-ART] Pilot study).

Q44956453

Comparative safety of interleukin-1 blockade with anakinra in patients with ST-segment elevation acute myocardial infarction (from the VCU-ART and VCU-ART2 pilot studies).

Q45006820

Peri-procedural tight glycemic control during early percutaneous coronary intervention up-regulates endothelial progenitor cell level and differentiation during acute ST-elevation myocardial infarction: effects on myocardial salvage

Q45012759

Usefulness of fetuin-A and C-reactive protein concentrations for prediction of outcome in acute coronary syndromes (from the French Registry of Acute ST-Elevation Non-ST-Elevation Myocardial Infarction [FAST-MI]).

Q45087884

Effects of incretin treatment on cardiovascular outcomes in diabetic STEMI-patients with culprit obstructive and multivessel non obstructive-coronary-stenosis

Q47102429

C-reactive protein, infarct size, microvascular obstruction, and left-ventricular remodelling following acute myocardial infarction

Q47191457

Evolution of left ventricular ejection fraction and its relationship to infarct size after acute myocardial infarction

Q47280593

Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial

Q47394886

Improved risk stratification of patients with acute coronary syndromes using a combination of hsTnT, NT-proBNP and hsCRP with the GRACE score

Q47597427

High-sensitivity C-reactive protein and long term reperfusion success of primary percutaneous intervention in ST-elevation myocardial infarction

Q47925976

Occurrence and predictors of left ventricular systolic dysfunction at hospital discharge and in long-term follow-up after acute myocardial infarction treated with primary percutaneous coronary intervention

Q48552397

Admission glucose and left ventricular systolic function in non-diabetic patients with acute myocardial infarction.

Q51067095

Prognostic value of C-reactive protein and cardiac troponin I in primary percutaneous interventions for ST-elevation myocardial infarction.

Q51095098

Relationship of cardiac biomarkers and reversible and irreversible myocardial injury following acute myocardial infarction as determined by cardiovascular magnetic resonance.

Q52844573

Biomarkers on admission for the prediction of cardiovascular events after primary stenting in patients with ST-elevation myocardial infarction.

Q53521922

How to use C-reactive protein in acute coronary care.

Q54644107

ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the diagnosis and treatment of acute and chronic heart failure 2008 of the European Society of Cardiology

Q55050673

Modulation of the interleukin-6 signalling pathway and incidence rates of atherosclerotic events and all-cause mortality: analyses from the Canakinumab Anti-Inflammatory Thrombosis Outcomes Study (CANTOS)

Q57182634

Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardio

Q57217547

C-Reactive Protein and Heart Failure after Myocardial Infarction in the Community

Q57540166

2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation

Q57621035

Cardiac resynchronization therapy with a defibrillator (CRTd) in failing heart patients with type 2 diabetes mellitus and treated by glucagon-like peptide 1 receptor agonists (GLP-1 RA) therapy vs. conventional hypoglycemic drugs: arrhythmic burden,

Q57801699

Rationale and design of the Virginia Commonwealth University-Anakinra Remodeling Trial-3 (VCU-ART3): A randomized, placebo-controlled, double-blinded, multicenter study

Q60177536

Usefulness of Canakinumab to Improve Exercise Capacity in Patients With Long-Term Systolic Heart Failure and Elevated C-Reactive Protein.

Q60177558

Management of acute myocardial infarction in patients presenting with ST-segment elevation

Q61651499

Influence on prognosis and morbidity of left ventricular ejection fraction with and without signs of left ventricular failure after acute myocardial infarction

Q68385673

Clinical application of C-reactive protein across the spectrum of acute coronary syndromes

Q80838278

Early inflammation and risk of long-term development of heart failure and mortality in survivors of acute myocardial infarction predictive role of C-reactive protein

Q82725159

C-reactive protein improves risk prediction in patients with acute coronary syndromes

Q84173219

Comparison of Three-year outcomes after primary percutaneous coronary intervention in patients with left ventricular ejection fraction <40% versus ≥ 40% (from the HORIZONS-AMI trial)

Q87414258

The usefulness of C-reactive protein for the prediction of post-infarct left ventricular systolic dysfunction and heart failure

Q88313972

Stretch, Injury and Inflammation Markers Evaluation to Predict Clinical Outcomes After Implantable Cardioverter Defibrillator Therapy in Heart Failure Patients With Metabolic Syndrome

Q89576043

Structural and myocardial dysfunction in heart failure beyond ejection fraction

Q91977748

Low-Dose Methotrexate for the Prevention of Atherosclerotic Events

Q92980641

P275

Creative Commons Attribution 4.0 International

copyrighted